Evaluation of the Efficacy of Nasal Sedation Midazolam Compared with Dexmedetomidine in the Management of Uncooperative Children with Down Syndrome during Dental Treatment. (16th September 2022)

• Record Type: Journal Article
• Authors: Hamod, Mohamad Nabil; Kouchaji, Chaza; Rostom, Faten; Alzoubi, Hasan; Katbeh, Imad; Tuturov, Nikolay
• Other Names: Leite Cavalcanti Alessandro Academic Editor.
• Is Part Of: International journal of dentistry. Volume 2022(2022)
• Publication Date: 2022-09-16
• Subjects: Dentistry -- Periodicals; Dentistry; Dentistry -- Periodicals; Electronic journals; Periodicals; 617.6
• DOI: 10.1155/2022/7344928
• Languages: English
• ISSNs: 1687-8728

Abstract

Abstract : Objective . This study aimed to compare the intranasal administration of midazolam and dexmedetomidine in uncooperative children with Down syndrome. Materials and Methods . The sample consisted of 20 children with Down syndrome aged 5 to 11 years who were divided equally into two groups: Group 1 (experimental) nasal dexmedetomidine and Group 2 (control) nasal midazolam. The efficacy of both the drugs was evaluated according to Ohio State University Behavioral Rating Scale (OSUBRS), University of Michigan scale (UMSS), and Houpt general behavior scale. Results . Both substances have been effective in the management of children with Down syndrome. There were no statistically significant differences for Ohio State University Behavioral Rating Scale (OSUBRS) (P value = 0.631), University of Michigan scale (UMSS) (P value = 0.739), and Houpt general behavior scale (P value = 0.481). Conclusion . Both midazolam and dexmedetomidine nasal can be used to sedate children with Down syndrome.